1 / 38

RV144: Clinical Development Plans

RV144: Clinical Development Plans. Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research. IAS 2012, Washington, DC USA

alyssa
Download Presentation

RV144: Clinical Development Plans

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RV144: Clinical Development Plans Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research IAS 2012, Washington, DC USA The views expressed are those of the presenter and should not be construed to represent the positions of the U.S. Army or DoD

  2. Past HIV Vaccine Concepts • Although only three concepts have undergone clinical efficacy testing to date, each HIV vaccine efficacy trial has yielded unexpected outcomes that have transformed the HIV landscape. 2003 2005 2007 2009 • 2003: AIDSVAX • VaxGenEnv gp120 • Humoral Immunity • Phase III studies in high-risk subjects in the US/Thailand • Elicited type-specific Abs but not broadly reactive NAbs • No efficacy • 2007: STEP-PHAMBILI STUDIES • Merck Ad5-Gag/Pol/Nef • Cellular Immunity • Phase IIb study in high-risk subjects in North/South America • Elicited cellular immunity by IFN-γ ELISPOT assays • No efficacy, possible increased HIV-1 acquisition • 2009: RV144 • Sanofi ALVAC prime, AIDSVAX gp120 boost • Humoral and Cellular Immunity • Phase III study in low-risk subjects in Thailand • 31% reduction in HIV-1 acquisition with no viral load effect Advancing HIV vaccine candidates to efficacy trials will accelerate progress in the field, bringing us closer to an effective global vaccine. 2

  3. NEJM 361:2209 (03 Dec 09)

  4. RV 144 demonstrated efficacyfor HIV acquisition C. Modified Intention-to-Treat Analysis* 1.0 0.9 Placebo 0.8 0.7 0.6 Probability of HIV Infection (%) 0.5 Vaccine 0.4 0.3 0.2 0.1 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Years N=16,395 51 vaccine, 74 placebo HIV infected Est. VE = 31% 95% CI 1-51% (p=0.04) Rerks-Ngarm et al. (2009, NEJM)

  5. What we have learned—RV 144 • Protection among low incidence heterosexual Thais, VE 31.2% at 42 months • No effect on post-infection viremia or CD4 count • Relatively monophyletic circulating variants CRF01_AE • Efficacy appears to be early and non-durable • Evoked binding Ab but not measurable, primary isolate Nab— BAb appeared early and decreased by > 10 fold over 6 months • CD4+ Env responses, but not CD8 responses • Correlate/surrogate studies limited by samples and endpoints

  6. What we would want next • Extend the observation of early 60% efficacy by increasing the durability of immune responses • Additional vaccine boosts • Improved adjuvants • Improved vaccines • Elucidate correlates of risk of infection. • Adequately powered studies • Adequate sample collections • Public health implementation--establish protection in higher incidence populations (additional boosts/improved adjuvants) • Heterosexuals in sub-Saharan Africa • MSM in Africa and Asia

  7. RV 144 correlates of risk—a teaser

  8. RV 144 Correlates Discovery Effort ADVISORY GROUPS PA H Steering Committee Product Development Advisory Group Clinical Development MHRP - DAIDS Steering Committee Humoral & Innate Immunity RV144 Steering Committee Cellular Immunity Scientific Steering Committee Host Genetics Correlates Animal Models Scientific Advisory Groups

  9. NEJM 366:1275 (05 Apr 2012)

  10. Multivariate Logistic Regression: Quantitative Variables All 6 variables together in multivariate analysis, P=0.08 Only a-EnvIgA and IgG gp70:V1V2 binding, p = 0.009 (log reg), 0.012 (Cox) 2 individual variables were significant: • gp70 V1V2 inversely correlates with infection [q = 0.08] • Estimated 43% reduction in infection rate (per SD) • Plasma IgAdirectly correlates with infection [q = 0.08] • Estimated 54% increase in infection rate (per SD)

  11. Is it V1V2 or both?

  12. Case control analysis of microarray shows trend to inverse correlation at tip of V2 and in CD4 binding site

  13. Sieve Analysis of RV144 Breakthrough Viruses supports importance of V2 loop

  14. Sieve Analysis of V2 • Comparison of viruses from HIV-1 infected vaccine versus HIV-1 infected placebo recipients • These are not transmitted/founder viruses—the mean time to last negative visit was ~ 3 months. • V2 was a major focus of analysis. • Analysis—collaboration between Dr. Morgane Rolland (MHRP), Dr. Jim Mullins (UW), SCHARP

  15. Sequence variation in position 169 Edlefsen, SCHARP

  16. Sequence variation in position 181 Edlefsen, SCHARP

  17. Results: Sites 169 and 181 Separately • For each site, VE significantly differs against match vs. mismatched infection • vaccine reduced infection rate 3.77 times more for 181-mm than 181-m • Positive VE for 169-matched infection and181-mismatched infection • The sieve analysis suggests that the vaccine selectively blocked acquisition with 169-matched and with 181-mismatched virus; but conferred no protection against 169-mismatched or 181-matched virus

  18. Correlates of Risk of Infection • WARNING—it is textbook (Stan Plotkin’s) knowledge that different vaccines for the same pathogen can have different correlates of risk/protection. • Will correlate of risk for ALVAC-AIDSVAX B/E in RV 144 generalize to…. • These products in Thai MSM? • ALVAC-gp120 engineered for heterosexuals in Africa? • Other HIV vaccines such as DNA/Ad5 (HVTN 505 phase IIb), Ad26-MVA, etc? • We want all subsequent efficacy trials to seek correlates—now more than ever. This impacts clinical design.

  19. Collaborators Duke Bart Haynes Larry Liao Georgia Tomaras Nathan Vandergrift Garnett Kelsoe David Montefiori Thomas Kepler Marcella Sarzotti-Kelsoe Munir Alam Bill and Melinda Gates Foundation Nina Russell Francine McCutchan HVTN Peter Gilbert Nicole Frahm Julie McElrath UMDNJ Abe Pinter NYU/VA Susan Zolla-Pazner Harvard Joseph Sodroski Steve Harrison Norm Letvin IHV George Lewis Tony DeVico • NIH VRC • Gary Nabel • Peter Kwong • John Mascola • Marie Pancera • Jason McLellan • Thai Ministry of Public Health

  20. Towards a Globally Effective HIV Vaccine

  21. 21 MHRP’s Product Development Plan • MHRP’s vaccine development strategy emphasizes regional and global approaches. 1 BUILDING ON RV144 REGIONAL VACCINE STRATEGY Building on the RV144 outcome and lessons learned, conduct efficacy trials of the prime-boost concept in: Thai MSM populations High-risk populations in Southern Africa 2 DIVERSIFYING AND REFINING THE PORTFOLIO GLOBAL VACCINE STRATEGY Pursuing diverse platforms (e.g. vectors, multi-valent constructs or mosaic inserts) that build on the prime-boost concept and readily translate to multi-clade testing and a globally effective vaccine.

  22. Pox-Protein Public Private Partnership(NIAID-Gates led)

  23. Planned studies are mutually reinforcing and will amplify public health impact and regional relevance. Focus on regional public health impact Precedent for vaccine efficacy Future amplification of global reach THAILAND High Risk MSM Mutually reinforcing studies strengthen and support public health benefit in target populations and the translation of the platform globally. US/EUROPE SOUTHEAST ASIA RV144 SOUTHERN AFRICA Republic of South Africa(RSA) High Risk Heterosexual • Strategy for achieving potential licensure in target markets and having the broadest public health impact. 23 May 2011

  24. Timeline Go/No-Go

  25. Short-term Development Objectives • Characterize vaccine immune responses using samples collected • In sufficient amounts • At the right times • From systemic as well as mucosal sites • Improve magnitude and durability of vaccine-induced responses

  26. Research Strategy Three Exploratory Phase II immunogenicity trials in Thailand • Collections: serum, plasma, cells, genital fluids • Special collections: leukapheresis, gut biopsy, cervical biopsy, bone marrow aspiration (except RV305) • Broad array of humoral and cellular assays

  27. RV305 (RV144 extended boost study) 135+27=162

  28. RV306 (Intensive Immunogenicity) 404+56=460

  29. Bridging Study—from AIDSVAX/alum to delta 11/MF59 • ALVAC-HIV prime as before • gp120 boost comparison: • One B and one E, both gD negative, C1 delta 11 • Novartis process and MF59 adjuvant • Part A Open Label safety assessment in the U.S. for Novartis product: A=ALVAC-HIV, N=Novartis rgp120B/E

  30. Bridging Study Part B Thailand—compare AIDSVAX/alum vs Novartis gp120/MF59 A=ALVAC-HIV, AVX=AIDSVAX B/E, N=Novartis rgp120B/E *Possibly use RV306 samples

  31. Pox-Protein Development Plan S. Africa ph2b Research Population: Heterosexual, high-risk Products: DNA + NYVAC (sanofi) + gp140 (Polymun)/MF59 (NVD) vs. NYVAC (sanofi) + gp140 (Polymun)/MF59 (NVD) Objective: Extend results & accelerate evaluation of other products using adaptive trial design and first available protein Partners/Funders: NIH, HVTN, sanofi pasteur, Novartis, BMGF Ongoing RV144 Follow-up in Thailand • Studies: • RV144i immune correlates studies • RV305 protein boosting study • RV306 expanded immunogenicity study • Objective: • Determine correlate of protection • for use in future trials; optimize the regimen • Partners/Funders: • US Army, Thai Gov’t, NIH, sanofi pasteur, BMGF Thailand ph2b Population: MSM, high-risk Products: ALVAC (sanofi) + gp120/MF59 (NVD) Objective: Confirm result & demonstrate efficacy in target population with potential for licensure Partners/Funders: US Army, Thai Gov’t, NIH, sanofi, BMGF? Licensure Africa ph2b Candidate selection Population: Heterosexual, high-risk Products: ALVAC (sanofi) + gp120/MF59 (NVD) Objective: Extend result & translate vaccine to Africa, other high-risk groups Partners/Funders: NIH, HVTN, sanofi, Novartis, BMGF, RSA? • ALVAC is default vector prime • Proteins boosts TBD • RV144 immune correlates • Immune grid • Cost, product availability 31

  32. Ad26-MVA +/- proteinBarouch et al Nature 482:89-93 02 Feb 2012

  33. Nature 482, 89–93 (02 February 2012) 100 80 DNA/MVA 60 MVA/MVA % Uninfected Ad26/MVA 40 MVA/Ad26 20 Sham 0 0 2 4 6 8 Number of IR Challenges

  34. MVA/Ad26 and Ad26/MVA Regimens Lower Early Setpoint Viral Loads Following SIVmac251 Infection Sham MVA/MVA DNA/MVA 6.09 5.75 Log SIV RNA 5.47 Days Following Infection Days Following Infection Days Following Infection Ad26/MVA 3x resistance to infection 4/8 : viremia blunted 1 log 3/8 : rapid virologic control 1/8 : persistently uninfected MVA/Ad26 Log SIV RNA 4.55 3.83 Days Following Infection Days Following Infection

  35. Protection Against Acquisition of IR SIVmac251 by Ad35/Ad26-SIVsmE543GagPolEnv Vaccine

  36. Ad26-MVA correlates analysis • Acquisition endpoint. • envelope binding antibody r= .79 p<.0001. • neutralization antibody r=.50 p=.0034 • ADCC r=.38 p=.034 (trend) • set point viral load endpoint, Many correlates (N=27); • prechallenge gag elispot count and gag elispot breadth were both correlated (r=-.50 p=.006 and r=-.64 p=.0002, respectively) with the endpoint. • peak envelope binding antibody r=-.70 followed by prechallengeneutralizing antibody r=.67.

  37. Summary • RV 144 demonstrated that vaccines can provide HIV acquisition protection. • Correlates of risk of infection were discovered in RV 144. • Correlates of risk of infection in Ad26-MVA (and other) vaccines have been discovered in NHP models. • We must educate (and remind) ourselves that correlates of risk may or may not generalize. • There is great value (but at a cost) to seek correlates of infection risk in future HIV vaccine trials. • Product development and scientific rationale must communicate with each other.

  38. Acknowledgements Supported by: Collaboration for AIDS Vaccine Discovery Grant From the Bill and Melinda Gates Foundation HVTN, DAIDS, NIAID With Collaborations with the MHRP and Thai Ministry of Public Health • National Institute of Allergy and Infectious Diseases (NIAID) • National Institutes of Health (NIH) • Division of AIDS (DAIDS) • U.S. Department of Health and Human Services (HHS) Center for HIV/AIDS Vaccine Immunology (CHAVI) # U19 AI067854-06 HVTN

More Related